Myasthenic crisis in the setting of Coronavirus Disease 2019 (COVID-19) - 18/11/20
Highlights |
• | A patient with Myasthenia Gravis (MG) on immunosuppressive therapy with underlying respiratory compromise may be more susceptible to infection with COVID-19 or severe manifestations of the virus. |
• | It is theorized that patients with MG may be more vulnerable to bacterial and viral infections, due to respiratory muscle weakness and use of immunosuppressive medications. |
• | It is critical for practitioners to be prepared for severe respiratory compromise in patients with MG and concomitant COVID-19 superinfection. |
• | In light of the COVID-19 pandemic, MG patients should be encouraged to continue their current treatment regimens, but engage in extra vigilant social distancing. |
Vol 67
Article 110001- décembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.